Avoids use of sales agents to mitigate against overselling
Teva leads in its efforts to mitigate the risk overselling by avoiding the use of a sales force to promote any of its antibacterial or antifungal medicines.
One of the main drivers for AMR is the overuse and misuse of antimicrobial products, causing antimicrobials to become ineffective more rapidly. Sales practices can promote overuse and misuse, especially when company business models rely on making high volumes of sales. To avoid this, pharmaceutical companies should take steps to ensure their products are used appropriately and only when needed. In choosing not to promote their products, companies can lower the risk of inappropriate use and help limit the spread of resistance.
What does Teva's best practice look like?
Teva demonstrates best practice: it does not use any sales agents to promote its antibacterial and antifungal medicines and thus removes any risk of this type of activity increasing inappropriate use of its products. It may be easier for generic medicine manufacturers to avoid the use of sales agents than for large research-based pharmaceutical companies, as lower prices allow these manufacturers to take part in tenders, which do not involve promotion.